[
  {
    "date": "2019-09-30",
    "symbol": "EPIX",
    "period": "FY",
    "entityregistrantname": "ESSA Pharma Inc.",
    "entitycentralindexkey": 1633932,
    "tradingsymbol": "EPIX",
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "currentfiscalyearenddate": "--09-30",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityshellcompany": "false",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": 20762374,
    "documenttype": "20-F",
    "documentperiodenddate": "2019-09-30",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2019,
    "documentfiscalperiodfocus": "FY",
    "cashandcashequivalents": 53322723,
    "currentreceivablesfromtaxcreditsandother": 360800,
    "currentprepaidexpenses": 615485,
    "currentassets": 54299008,
    "noncurrentdeposits": 274085,
    "intangibleassetsotherthangoodwill": 361284,
    "assets": 54773824,
    "tradeandothercurrentpayables": 1565789,
    "currentportionoflongtermborrowings": 3708955,
    "currenttaxliabilitiescurrent": 300000,
    "currentliabilities": 5574744,
    "noncurrentderivativefinancialliabilities": 18179,
    "liabilities": 5592923,
    "issuedcapital": 76212154,
    "reserveofsharebasedpayments": 29856177,
    "accumulatedothercomprehensiveincome": -2076479,
    "retainedearnings": -54810951,
    "equity": -54810951,
    "equityandliabilities": 54773824,
    "researchanddevelopmentexpense": 6696234,
    "financecosts": 602744,
    "generalandadministrativeexpense": 5473486,
    "operatingexpense": 12772464,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 7845,
    "financeincome": 26251,
    "gainslossesonchangeinfairvalueofderivatives": 310,
    "gainlossonassetacquisition": 2332954,
    "profitlossbeforetax": -10403945,
    "incometaxexpensecontinuingoperations": 37920,
    "comprehensiveincome": -10441865,
    "basicanddilutedearningslosspershare": -1.24,
    "weightedaverageshares": 8433441,
    "profitloss": -10441865,
    "amortizationexpenseoftangibleandintangibleassets": 18297,
    "adjustmentsforfinancecosts": 602744,
    "adjustmentsforunrealisedforeignexchangelossesgains": 16457,
    "adjustmentsforsharebasedpayments": 1146707,
    "adjustmentsfordecreaseincreaseincurrentreceivablesfromtaxcreditsandother": -59665,
    "adjustmentsforincreasedecreaseinprepaidexpenses": -179416,
    "adjustmentsforincreasedecreaseinaccountpayableandaccruedliabilities": -1014049,
    "incometaxespaidrefundclassifiedasoperatingactivities": 4722,
    "cashflowsfromusedinoperatingactivities": -12249935,
    "depositsclassifiedasinvestingactivities": 201399,
    "paymentofcostsassociatedwithterminationofsublease": 246906,
    "cashflowsfromusedininvestingactivities": -45507,
    "proceedsfromcashacquiredonassetacquisition": 22244248,
    "paymentsfortransactioncostsonassetacquisition": 1860341,
    "proceedsonequityfinancing": 36000000,
    "paymentsforshareissuecosts": 2362329,
    "repaymentsofnoncurrentborrowings": 2808823,
    "interestpaidclassifiedasfinancingactivities": 10503,
    "cashflowsfromusedinfinancingactivities": 50810826,
    "effectofexchangeratechangesoncashandcashequivalents": -21805,
    "increasedecreaseincashandcashequivalents": 38493579,
    "numberofsharesissued": 20762374,
    "increasedecreasethroughacquisitionofsubsidiary": 15989197,
    "increasedecreasethroughofsubsidiaryshares": 6718150,
    "increasedecreasethroughtransactionswithowners": 12161192,
    "increasedecreasethroughtransactionswithownersshares": 6080596,
    "increasedecreesinshareissuancecosts": 901298,
    "increasedecreasethroughexerciseofwarrantsequity": 8757066,
    "increasedecreasethroughexerciseofwarrantsequityshares": 2187530,
    "increasedecreasethroughsharebasedpaymenttransactions": 1146707,
    "proportionofownershipinterestinsubsidiary": 1,
    "percentageofdepreciation": 0.2,
    "depreciationmethodpropertyplantandequipment": "straight-line method",
    "leaseliabilities": 165500,
    "rightofuseassets": 165500,
    "acquisitionrelatedcostsfortransactionrecognisedseparatelyfromacquisitionofassetsandassumptionofliabilitiesinbusinesscombination": 64804,
    "costsassociatedwithterminationofsublease": 246906,
    "prepaidinsuranceexpense": 524257,
    "otherdepositsandprepaidexpenses": 91228,
    "amortisationexpense": 18297,
    "minimumadvanceroyaltypayments": 85000,
    "amountofmilestonepaymentsatstartofsecondphaseclinicaltrial": 50000,
    "amountofmilestonepaymentsatstartofthirdphaseclinicaltrial": 900000,
    "amountofmilestonepaymentsatapplicationformarketingapproval": 1450000,
    "borrowingslessunaccretedtransactioncosts": 3708955,
    "repaymentsofborrowingsclassifiedasfinancingactivities": 2953968,
    "accretioncost": 602744,
    "significantunobservableinputliabilities": 0.0331,
    "warrantlifewarrantsissued": "P3Y3M22D",
    "derivativefinancialliabilities": 18179,
    "financialliabilitiesatfairvalue": 1659,
    "sensitivityanalysisoffairvalueincreaseinderivativewarrantsimpactoftenpercentincreaseinmarketprice": 4945,
    "sensitivityanalysisoffairvaluedecreaseinderivativewarrantsimpactoftenpercentdecreaseinmarketprice": 4316,
    "sensitivityanalysisoffairvalueincreaseinderivativewarrantsimpactoftenpercentincreaseinvolatility": 14343,
    "sensitivityanalysisoffairvaluedecreaseinderivativewarrantsimpactoftenpercentdecreaseinvolatility": 9569,
    "numberofoutstandingshareoptions": 45000,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 202000,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 32998,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 397370,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement2019": 4.59,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement2019": 3.77,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement2019": 4.1,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement2019": 5.88,
    "exercisepriceofoutstandingshareoptions2019": 5.06,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions2019": "P9Y4M13D",
    "expensefromsharebasedpaymenttransactionswithemployees": 304786,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0255,
    "descriptionofoptionlifeshareoptionsgranted": 10,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.7933,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 11919404,
    "numberofinstrumentsotherequityinstrumentsgranted": 11919404,
    "numberofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement": 2188999,
    "numberofinstrumentsotherequityinstrumentsexpired": 1250,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement2019": 0.0001,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement2019": 0.0001,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisedorvestedinsharebasedpaymentarrangement2019": 0.002,
    "weightedaverageexercisepriceofotherequityinstrumentsexpiredinsharebasedpaymentarrangement2019": 31.17,
    "expirationdateofwarrants": "August 23, 2024",
    "sharesreservedforissueunderoptionsandcontractsforsaleofshares": 2563991,
    "termsofsharesreservedforissueunderoptionsandcontractsforsaleofshares": "P10Y",
    "purchaserightgrantspercentageonmarketpriceminimum": 0.85,
    "purchaserightspurchaseperiod": "P24M",
    "sharebasedcompensationarrangementbyshare-basedpaymentawardoptiongrantsinperiodweightedaveragegrantdatefairvalue": 3,
    "numberofcommonsharesexerciseofwarrantsequityshares": 1652530,
    "numberofprefundedwarrantissuedforcommonshares": 1653999,
    "shareissuancecostthroughaccountspayableandaccruedliabilities": 303951,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2107096,
    "keymanagementpersonnelcompensationsharebasedpayment": 1006143,
    "keymanagementpersonnelcompensation": 3113239,
    "amountspayablerelatedpartytransactions": 108331,
    "periodofbasesalarypaiduponterminationwithoutcause": "P1Y",
    "periodofsalaryentitledifterminationwithoutcauseoccursafterorwithin60dayspriortochangeofcontrolevent": "P18M",
    "periodofsalaryentitledifterminationwithoutcauseoccurswithin18monthsafterchangeofcontrolevent": "P18M",
    "taxexpenseincomeatapplicabletaxrate": -2688000,
    "reconciliationofnondeductiblesharebasedpayments": 310000,
    "taxeffectofacquisitiongain": 1297000,
    "reconciliationofotherpermanentdifferencesincludingforeignexchange": 7000,
    "taxeffectoftaxlosses": -720000,
    "taxeffectofforeigntaxrates": 443920,
    "taxeffectfromchangeintaxrate": -196000,
    "taxeffectofchangeinunrecognizedoftemporarydifference": 4178000,
    "componentsofoperatinglossescarriedforward": 67215000,
    "componentsofinvestmenttaxcredits": 149000,
    "componentsofequipmentandintangibleassets": 85000,
    "componentsoffinancingcosts": 5832000,
    "operatinglossescarriedforwardexpirationperiod": "Expire from 2031 â€“ 2039",
    "financingcostsexpirationperiod": "Expire from 2040 to 2044",
    "investmenttaxcreditsexpirationperiod": "Expire in 2035",
    "applicabletaxrate": 0.21,
    "federalandprovincialgeneralcorporateincometaxrate": 0.27,
    "generalcorporateincometaxrate": 0.12,
    "fairvalueofprincipalandfinancingcosts": 3926075,
    "workingcapital": 48724264,
    "termofdebtinstrument": "P33M",
    "longtermdebtmaturity": "2020-09-01",
    "sensitivityanalysisimpactof10percentchangeininterestrateincreaseinrealizednetloss": 11371,
    "sensitivityanalysisimpactof10percentchangeininterestratedecreaseinrealizednetloss": 40146,
    "sensitivityanalysisimpactof10percentchangeinforeignexchangeratebetweencadandusdfluctuationinrealizednetloss": 21465,
    "obligationsforloanpayments": 4045500,
    "leaseonofficespaces": 119383,
    "remainingbalanceexpectedtobereceivedaftercompletionofgrantterm": 229201,
    "researchanddevelopmentexpenseallocationclinical": 80021,
    "consultingfee": 301817,
    "researchanddevelopmentexpenseallocationlegalpatentsandlicensefees": 781133,
    "researchanddevelopmentexpenseallocationmanufacturingexpense": 946705,
    "otherexpensebynature": 111750,
    "researchanddevelopmentexpenseallocationpreclinicalexpense": 2789753,
    "researchanddevelopmentexpenseallocationprogramadministrationexpense": 254970,
    "royaltyexpense": 65405,
    "wagesandsalaries": 1012344,
    "travelexpense": 47550,
    "generalandadministrativeexpenseallocationconsultingandsubcontractorfeesexpense": 142780,
    "generalandadministrativeexpenseallocationdirectorfeesexpense": 252000,
    "insuranceexpense": 471852,
    "generalandadministrativeexpenseallocationinvestorrelationsexpense": 319373,
    "generalandadministrativeexpenseallocationofficeitandcommunications": 155208,
    "professionalfeesexpense": 675412,
    "generalandadministrativeexpenseallocationregulatoryfeesandtransferagent": 91764,
    "generalandadministrativeexpenseallocationrentexpense": 192479,
    "repaymentsofaggregateborrowingsclassifiedasfinancingactivities": 3652471,
    "finalpaymentofborrowingsclassifiedasfinancingactivities": 688000
  },
  {
    "date": "2018-09-30",
    "symbol": "EPIX",
    "period": "FY",
    "entityregistrantname": "ESSA Pharma Inc.",
    "entitycentralindexkey": 1633932,
    "entitycurrentreportingstatus": "Yes",
    "entityvoluntaryfilers": "No",
    "currentfiscalyearenddate": "--09-30",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "entityshellcompany": "false",
    "entitywellknownseasonedissuer": "No",
    "entitycommonstocksharesoutstanding": 5776098,
    "documenttype": "20-F",
    "documentperiodenddate": "2018-09-30",
    "amendmentflag": "false",
    "documentfiscalyearfocus": 2018,
    "documentfiscalperiodfocus": "FY",
    "cashandcashequivalents": 14829144,
    "currentreceivablesfromtaxcreditsandother": 297349,
    "currentprepaidexpenses": 470154,
    "currentassets": 15596647,
    "noncurrentdeposits": 201399,
    "intangibleassetsotherthangoodwill": 219028,
    "assets": 16017074,
    "tradeandothercurrentpayables": 523669,
    "currentportionoflongtermborrowings": 2815947,
    "currenttaxliabilitiescurrent": 4722,
    "currentliabilities": 3344338,
    "longtermborrowings": 3501016,
    "noncurrentderivativefinancialliabilities": 19648,
    "liabilities": 6865002,
    "issuedcapital": 40205997,
    "reserveofsharebasedpayments": 15391640,
    "accumulatedothercomprehensiveincome": -2076479,
    "retainedearnings": -44369086,
    "equity": -44369086,
    "equityandliabilities": 16017074,
    "researchanddevelopmentexpense": 4873335,
    "financecosts": 911959,
    "generalandadministrativeexpense": 5928671,
    "operatingexpense": 11713965,
    "gainslossesonexchangedifferencesontranslationrecognisedinprofitorloss": 1417,
    "financeincome": 42734,
    "lossesondisposalsofpropertyplantandequipment": 83692,
    "gainslossesonchangeinfairvalueofderivatives": 8306,
    "profitlossbeforetax": -11602411,
    "incometaxexpensecontinuingoperations": 27029,
    "profitloss": -11629440,
    "comprehensiveincome": -11629440,
    "basicanddilutedearningslosspershare": -2.55,
    "weightedaverageshares": 4566519,
    "amortizationexpenseoftangibleandintangibleassets": 34488,
    "adjustmentsforfinancecosts": 911959,
    "revenuefromgovernmentgrants": 229201,
    "adjustmentsforunrealisedforeignexchangelossesgains": 19694,
    "adjustmentsforsharebasedpayments": 1401414,
    "adjustmentsfordecreaseincreaseincurrentreceivablesfromtaxcreditsandother": -35874,
    "adjustmentsforincreasedecreaseinprepaidexpenses": 601949,
    "adjustmentsforincreasedecreaseinaccountpayableandaccruedliabilities": -1120833,
    "incometaxespaidrefundclassifiedasoperatingactivities": 104799,
    "cashflowsfromusedinoperatingactivities": -10218046,
    "depositsclassifiedasinvestingactivities": -201399,
    "cashflowsfromusedininvestingactivities": -201399,
    "proceedsonequityfinancing": 26040000,
    "paymentsforshareissuecosts": 2174826,
    "repaymentsofnoncurrentborrowings": 1991378,
    "interestpaidclassifiedasfinancingactivities": 563298,
    "cashflowsfromusedinfinancingactivities": 21310498,
    "effectofexchangeratechangesoncashandcashequivalents": -19094,
    "increasedecreaseincashandcashequivalents": 10871959,
    "numberofsharesissued": 5776098,
    "increasedecreasethroughtransactionswithowners": 8756000,
    "increasedecreasethroughtransactionswithownersshares": 4321000,
    "shareissuerelatedcost": 672221,
    "increasedecreasethroughsharebasedpaymenttransactions": 1401414,
    "percentageofdepreciation": 0.2,
    "depreciationmethodpropertyplantandequipment": "straight-line method",
    "prepaidinsuranceexpense": 381098,
    "otherdepositsandprepaidexpenses": 89056,
    "amortizationexpensefortangibleassets": 16190,
    "disposalspropertyplantandequipment": 113985,
    "amortisationexpense": 18298,
    "minimumadvanceroyaltypayments": 85000,
    "amountofmilestonepaymentsatstartofsecondphaseclinicaltrial": 50000,
    "amountofmilestonepaymentsatstartofthirdphaseclinicaltrial": 900000,
    "amountofmilestonepaymentsatapplicationformarketingapproval": 1450000,
    "borrowingslessunaccretedtransactioncosts": 6316963,
    "repaymentsofborrowingsclassifiedasfinancingactivities": -1991378,
    "accretioncost": 911959,
    "borrowingsinterestrate": 0.1215,
    "riskfreeinterestratewarrantsissued": 0.0306,
    "warrantlifewarrantsissued": "P4Y3M14D",
    "historicalvolatilityforsharessignificantunobservableinputsliabilities": 0.68,
    "derivativefinancialliabilities": 19648,
    "financialliabilitiesatfairvalue": 1969,
    "sensitivityanalysisoffairvalueincreaseinderivativewarrantsimpactoftenpercentincreaseinmarketprice": 5057,
    "sensitivityanalysisoffairvaluedecreaseinderivativewarrantsimpactoftenpercentdecreaseinmarketprice": 4503,
    "sensitivityanalysisoffairvalueincreaseinderivativewarrantsimpactoftenpercentincreaseinvolatility": 14598,
    "sensitivityanalysisoffairvaluedecreaseinderivativewarrantsimpactoftenpercentdecreaseinvolatility": 10039,
    "subscriptionpricepershare": 4,
    "numberofoutstandingshareoptions": 83350,
    "numberofshareoptionsgrantedinsharebasedpaymentarrangement": 12000,
    "numberofshareoptionsexpiredinsharebasedpaymentarrangement": 88817,
    "numberofshareoptionsexercisableinsharebasedpaymentarrangement": 152530,
    "weightedaverageexercisepriceofshareoptionsoutstandinginsharebasedpaymentarrangement": 4.8,
    "weightedaverageexercisepriceofshareoptionsgrantedinsharebasedpaymentarrangement": 3.94,
    "weightedaverageexercisepriceofshareoptionsexpiredinsharebasedpaymentarrangement": 21.83,
    "weightedaverageexercisepriceofshareoptionsexercisableinsharebasedpaymentarrangement": 9.06,
    "exercisepriceofoutstandingshareoptions": 4,
    "weightedaverageremainingcontractuallifeofoutstandingshareoptions": 1.08,
    "expensefromsharebasedpaymenttransactionswithemployees": 78747,
    "descriptionofriskfreeinterestrateshareoptionsgranted": 0.0266,
    "descriptionofoptionlifeshareoptionsgranted": 7.28,
    "descriptionofexpectedvolatilityshareoptionsgranted": 0.778,
    "numberofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 535000,
    "numberofinstrumentsotherequityinstrumentsgranted": 2427937,
    "numberofinstrumentsotherequityinstrumentsexpired": 113636,
    "numberofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 2663936,
    "weightedaverageexercisepriceofotherequityinstrumentsoutstandinginsharebasedpaymentarrangement": 4,
    "weightedaverageexercisepriceofotherequityinstrumentsgrantedinsharebasedpaymentarrangement": 0.4,
    "weightedaverageexercisepriceofotherequityinstrumentscancelledorexpiredinsharebasedpaymentarrangement": 66,
    "weightedaverageexercisepriceofotherequityinstrumentsexercisableinsharebasedpaymentarrangement": 6.13,
    "sharesreservedforissueunderoptionsandcontractsforsaleofshares": 1155218,
    "termsofsharesreservedforissueunderoptionsandcontractsforsaleofshares": "P10Y",
    "sharebasedcompensationarrangementbyshare-basedpaymentawardoptiongrantsinperiodweightedaveragegrantdatefairvalue": 3.08,
    "expirydateofoutstandingstockoptions": "August 9, 2026",
    "valueforissuingbrokerwarrant": 672221,
    "keymanagementpersonnelcompensationshorttermemployeebenefits": 2439422,
    "keymanagementpersonnelcompensationsharebasedpayment": 1429053,
    "keymanagementpersonnelcompensation": 3868475,
    "numberofshareoptionsmodifiedinsharebasedpaymentarrangement": 73000,
    "amountspayablerelatedpartytransactions": 128035,
    "periodofbasesalarypaiduponterminationwithoutcause": "P1Y",
    "periodofsalaryentitledifterminationwithoutcauseoccursafterorwithin60dayspriortochangeofcontrolevent": "P18M",
    "periodofsalaryentitledifterminationwithoutcauseoccurswithin18monthsafterchangeofcontrolevent": "P18M",
    "taxexpenseincomeatapplicabletaxrate": -3104000,
    "reconciliationofnondeductiblesharebasedpayments": 378000,
    "reconciliationofotherpermanentdifferencesincludingforeignexchange": -41000,
    "taxeffectoftaxlosses": -638000,
    "taxeffectofforeigntaxrates": -463000,
    "taxeffectfromchangeintaxrate": 290000,
    "taxeffectofchangeinunrecognizedoftemporarydifference": 3605029,
    "componentsofoperatinglossescarriedforward": 53568000,
    "componentsofinvestmenttaxcredits": 149000,
    "componentsofequipmentandintangibleassets": 128000,
    "componentsoffinancingcosts": 2771000,
    "operatinglossescarriedforwardexpirationperiod": "Expire from 2031 - 2038",
    "financingcostsexpirationperiod": "Expire from 2039 to 2042",
    "investmenttaxcreditsexpirationperiod": "Expire in 2035",
    "fairvalueofprincipalandfinancingcosts": 6736846,
    "workingcapital": 12453708,
    "termofdebtinstrument": "P33M",
    "longtermdebtmaturity": "2020-09-01",
    "sensitivityanalysisimpactof10percentchangeininterestrateincreaseinrealizednetloss": 81065,
    "sensitivityanalysisimpactof10percentchangeininterestratedecreaseinrealizednetloss": 3329,
    "sensitivityanalysisimpactof10percentchangeinforeignexchangeratebetweencadandusdfluctuationinrealizednetloss": 13751,
    "paymentsforcontractualobligations": 174037,
    "minimumannualroyaltyandpaymentsforcontractualobligations": 85000,
    "obligationsforloanpayments": 4032332,
    "leaseonofficespaces": 70670,
    "remainingbalanceexpectedtobereceivedaftercompletionofgrantterm": 229201,
    "researchanddevelopmentexpenseallocationclinical": 1177179,
    "consultingfee": 624879,
    "researchanddevelopmentexpenseallocationlegalpatentsandlicensefees": 561099,
    "researchanddevelopmentexpenseallocationmanufacturingexpense": 219526,
    "otherexpensebynature": 40845,
    "researchanddevelopmentexpenseallocationpharmacologyexpense": 372509,
    "researchanddevelopmentexpenseallocationpreclinicalexpense": 446748,
    "researchanddevelopmentexpenseallocationprogramadministrationexpense": 385085,
    "royaltyexpense": 66929,
    "wagesandsalaries": 2010613,
    "travelexpense": 184032,
    "generalandadministrativeexpenseallocationconsultingandsubcontractorfeesexpense": 96986,
    "generalandadministrativeexpenseallocationdirectorfeesexpense": 196472,
    "insuranceexpense": 449972,
    "generalandadministrativeexpenseallocationinvestorrelationsexpense": 235416,
    "generalandadministrativeexpenseallocationofficeitandcommunications": 216714,
    "professionalfeesexpense": 860435,
    "generalandadministrativeexpenseallocationregulatoryfeesandtransferagent": 150913,
    "generalandadministrativeexpenseallocationrentexpense": 415744,
    "numberofprefundedwarrantissuedforcommonshares": 535000,
    "exercisepriceshareoptionsgranted": 3.58,
    "termofexercisablestockoption": "P10Y"
  }
]